June 10, 2025 – The FDA has approved a new shot to prevent respiratory syncytial virus (RSV) infection in babies during their first RSV season, which typically lasts from fall through spring.

New UK data shows RSV vaccines in pregnant women cut infant hospitalizations by 72%, while premature babies are now protected with a new antibody shot offering immediate, 6-month immunity.

After a median follow-up of 30.6 months, a single dose of RSVPreF3 OA reduced symptomatic RSV-LRTD by 62.9% (97.5% CI 46.7–74.8) over three RSV seasons.

RSV is a common virus that causes coughs and colds but can lead to a severe lung infection called bronchiolitis, which can be dangerous in babies, with some requiring admission to intensive care.

RSV is a virus that infects the nose, throat, and lungs and is often difficult to distinguish from other respiratory viruses, according to the Centers for Disease Control and Prevention.

The RSV hospitalization rate for those up to 7 months old fell 28 percent from around 15 per 1,000 children in 2018–2020 to around 11 per 1,000 children this past winter.

The FDA has granted clearance to TytoCare’s AI-powered Tyto Insights for Lung Sounds to detect rhonchi, marking the third lung sound alongside wheeze and crackles to receive the designation ...

RSV sent fewer babies to the hospital last winter, after new treatment and vaccine arrived New tools may have reduced cases of severe respiratory illness, CDC says A pediatric visit in Denver.

Using a two-dimensional convolutional neural network (CNN), the algorithm can classify breathing sounds and count wheezing events. The researchers trained the model with augmented lung-sound data.